Country: Կանադա
language: անգլերեն
source: Health Canada
ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE)
MYLAN PHARMACEUTICALS ULC
N06BA09
ATOMOXETINE
60MG
CAPSULE
ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) 60MG
ORAL
30/100
Prescription
MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
Active ingredient group (AIG) number: 0150434005; AHFS:
CANCELLED POST MARKET
2018-07-12
MYLAN-ATOMOXETINE Product Monograph Page 1 PRODUCT MONOGRAPH PR MYLAN-ATOMOXETINE (ATOMOXETINE CAPSULES, USP) 18 MG, 25 MG, 40 MG, 60 MG, 80 MG AND 100 MG ATOMOXETINE (AS ATOMOXETINE HYDROCHLORIDE) SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) MYLAN PHARMACEUTICALS ULC Date of Revision: 85 Advance Rd. January 7, 2016 Etobicoke, On, M8Z 2S6 Canada SUBMISSION CONTROL NO: 190331 MYLAN-ATOMOXETINE Product Monograph Page 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 SPECIAL DIAGNOSTIC CONSIDERATIONS ....................................................................... 3 NEED FOR COMPREHENSIVE TREATMENT PROGRAM ............................................... 4 CONTRAINDICATIONS ............................................................................................................ 4 WARNINGS AND PRECAUTIONS ......................................................................................... 5 ADVERSE REACTIONS .......................................................................................................... 12 DRUG ABUSE AND DEPENDENCE ..................................................................................... 21 DRUG INTERACTIONS ........................................................................................................... 22 DOSAGE AND ADMINISTRATION ..................................................................................... 24 OVERDOSAGE .......................................................................................................................... 27 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 28 STORAGE AND STABILITY ........................................ read_full_document